Glicorest (Metformin Hydrochloride, Glibenclamide)

Glicorest is indicated for the treatment of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy are insufficient to achieve target glycemic levels.

• Improves fasting plasma glucose by reducing hepatic glucose output (metformin component).
• Lowers post‑prandial glucose through enhanced insulin secretion (glibenclamide component).
• Can be used as part of a combination regimen with other oral antidiabetic agents.
• May be considered when a single‑pill regimen is preferred to simplify therapy.
• Supports overall HbA1c reduction when taken as prescribed.

The safety profile of Glicorest reflects the known effects of its two active ingredients, metformin and glibenclamide.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea.
• Mild hypoglycemia, especially when meals are skipped or delayed.
• Headache or dizziness.
• Metallic taste in the mouth.

Serious

• Lactic acidosis, a rare metabolic emergency associated with metformin.
• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including skin rash, itching, or swelling.
• Hepatotoxicity or significant elevation of liver enzymes.

Before initiating Glicorest, clinicians should evaluate patient-specific factors and monitor for conditions that may increase risk.

• Assess renal function; metformin is contraindicated in severe renal impairment.
• Review hepatic status, as liver disease may predispose to lactic acidosis.
• Use caution in elderly patients who are more susceptible to hypoglycemia.
• Avoid use during acute or chronic metabolic acidosis.
• Monitor for signs of heart failure, which can affect drug clearance.
• Evaluate pregnancy or lactation status; safety data are limited.

Glicorest may interact with several medications; understanding these interactions helps minimize adverse outcomes.

Avoid

• Concurrent use of other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Strong inhibitors of renal tubular secretion of metformin (e.g., cimetidine) that raise metformin levels.
• Iodinated contrast agents without appropriate hydration and monitoring.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Diuretics, especially thiazides, that can affect glucose control.
• Corticosteroids, which may increase blood glucose and require dose adjustments.
• Alcohol intake, which can potentiate metformin‑related lactic acidosis.